New AHS Consensus on Emergency Migraine Management

An estimated 1.2 million visits to US emergency departments for acute migraine take place every year. There is currently "a lot of variability" in the treatment of these attacks.Intravenous (IV) metoclopramide and prochlorperazine, and subcutaneous sumatriptan, should be offered to eligible adults presenting for the first time to an emergency department (ED) with acute migraine requiring treatment with injectable medication, according to new evidence-based recommendations.An expert panel, convened by the American Headache Society (AHS), also recommends that dexamethasone be offered to these patients to prevent recurrence of headache. Panel members also suggest that injectable morphine and hydromorphone be avoided as first-line therapies because of the lack of evidence demonstrating efficacy and concern about subacute or long-term sequelae.The recommendations were published online June 14 in Headache.http://onlinelibrary.wiley.com/doi/10.1111/head.12835/abstract 

Tags: